Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial.
Patients with end-stage renal disease have increased circulating concentrations of oxidatively modified circulating proteins. Therefore, we examined the ability of vitamin E alpha (alpha-tocopherol) to alter levels of these modified proteins. Randomized clinical trial. 27 clinically stable patients treated by means of hemodialysis in 4 freestanding outpatient dialysis units. Oral administration of 800 IU of vitamin E alpha or placebo daily. Plasma levels of alpha- and gamma-tocopherol and oxidative protein modifications reflecting 2 pathways for protein-oxidant damage. The advanced glycation end product pentosidine reflects glycoxidation. The lipid peroxidation products iso[4]-levuglandin E(2), (E)-4-hydroxy-2-nonenal, and (E)-4-oxo-2-nonenal are formed through covalent adduction. Circulating levels of all oxidative protein modifications were increased in patients with end-stage renal disease. Supplementation with alpha-tocopherol caused alpha-tocopherol levels to rise (13.2 +/- 3.7 to 27.3 +/- 14 mug/mL), but gamma-tocopherol levels to decrease (4.1 +/- 1.6 to 3.5 +/- 1.1 mug/mL). Control values were unchanged. There was no effect on oxidative protein modifications (placebo versus treatment; mean for pentosidine, 15.6 +/- 11.4 (SD): 95% confidence interval (CI), 8.2 to 23.1 versus 21.3 +/- 9.0 pg/mg protein; 95% CI, 16.1 to 26.6; iso[4]-levuglandin E(2), 8.31 +/- 2.55; 95% CI, 6.77 to 9.85 versus 8.46 +/- 2.37 nmol/mL; 95% CI, 7.09 to 9.84; (E)-4-hydroxy-2-nonenal, 0.51 +/- 0.11; 95% CI, 0.45 to 0.57 versus 0.51 +/- 0.08 nmol/mL; 95% CI, 0.46 to 0.56; (E)-4-oxo-2-nonenal, 189 +/- 44; 95% CI, 162 to 215 vs 227 +/- 72 pmol/mL; 95% CI, 183 to 271). Sample size was adequate to show changes in alpha- and gamma-tocopherol levels in response to treatment. However, power was insufficient to show an effect on oxidative protein modifications. Intervention of oral supplementation with alpha-tocopherol did not result in changes in circulating oxidative protein modifications. A larger study may be required to show an effect in this clinical setting.